JP2017141277A5 - - Google Patents

Download PDF

Info

Publication number
JP2017141277A5
JP2017141277A5 JP2017075145A JP2017075145A JP2017141277A5 JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5 JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017075145 A JP2017075145 A JP 2017075145A JP 2017141277 A5 JP2017141277 A5 JP 2017141277A5
Authority
JP
Japan
Prior art keywords
administration
pharmaceutical composition
pain
formulation
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017075145A
Other languages
English (en)
Japanese (ja)
Other versions
JP6423036B2 (ja
JP2017141277A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017141277A publication Critical patent/JP2017141277A/ja
Publication of JP2017141277A5 publication Critical patent/JP2017141277A5/ja
Application granted granted Critical
Publication of JP6423036B2 publication Critical patent/JP6423036B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017075145A 2010-06-15 2017-04-05 痛み治療用の医薬配合物 Expired - Fee Related JP6423036B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15
EP10006202.5 2010-06-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015151003A Division JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物

Publications (3)

Publication Number Publication Date
JP2017141277A JP2017141277A (ja) 2017-08-17
JP2017141277A5 true JP2017141277A5 (enExample) 2017-10-05
JP6423036B2 JP6423036B2 (ja) 2018-11-14

Family

ID=42395008

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013514579A Expired - Fee Related JP6133772B2 (ja) 2010-06-15 2011-06-14 痛み治療用の医薬配合物
JP2015151003A Expired - Fee Related JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物
JP2017075145A Expired - Fee Related JP6423036B2 (ja) 2010-06-15 2017-04-05 痛み治療用の医薬配合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013514579A Expired - Fee Related JP6133772B2 (ja) 2010-06-15 2011-06-14 痛み治療用の医薬配合物
JP2015151003A Expired - Fee Related JP6197007B2 (ja) 2010-06-15 2015-07-30 痛み治療用の医薬配合物

Country Status (29)

Country Link
US (3) US8846765B2 (enExample)
EP (2) EP2992877A1 (enExample)
JP (3) JP6133772B2 (enExample)
KR (1) KR101831616B1 (enExample)
CN (1) CN103108631B (enExample)
AR (1) AR081931A1 (enExample)
AU (2) AU2011267474B2 (enExample)
BR (1) BR112012031836A2 (enExample)
CA (1) CA2796774C (enExample)
CL (1) CL2012002551A1 (enExample)
CO (1) CO6602157A2 (enExample)
CY (1) CY1117118T1 (enExample)
DK (1) DK2582366T3 (enExample)
EC (2) ECSP12012217A (enExample)
ES (1) ES2560676T3 (enExample)
HK (1) HK1215787A1 (enExample)
HR (1) HRP20151327T1 (enExample)
HU (1) HUE026619T2 (enExample)
IL (1) IL221926A (enExample)
MX (1) MX2012014482A (enExample)
NZ (1) NZ602625A (enExample)
PE (2) PE20160531A1 (enExample)
PL (1) PL2582366T3 (enExample)
PT (1) PT2582366E (enExample)
RS (1) RS54439B1 (enExample)
RU (2) RU2589692C2 (enExample)
SI (1) SI2582366T1 (enExample)
WO (1) WO2011157391A1 (enExample)
ZA (1) ZA201208646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
HRP20240812T1 (hr) 2013-01-22 2024-09-27 Vistagen Therapeutics, Inc. Oblici doziranja i terapijska primjena l-4-klorokinurenina
US20140275278A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
WO2015171770A1 (en) * 2014-05-06 2015-11-12 Northwestern University Combinations of nmdar modulating compounds
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CN1309562A (zh) * 1998-07-16 2001-08-22 纪念斯隆-凯特林癌症中心 包括一种阿片样物质镇痛剂和一种nmda拮抗剂的局部给药组合物
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
EP1545461A4 (en) 2002-09-09 2011-06-22 Endo Pharmaceuticals Inc COMBINED ANALGESIC COMPOSITION WITH IMMEDIATE AND PROLONGED RELEASE
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
HRP20110271T1 (hr) 2006-04-28 2011-05-31 Grnenthal Gmbh Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
AU2007256352A1 (en) 2006-06-08 2007-12-13 Ucb Pharma Gmbh Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101730924B1 (ko) 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
RU2589692C2 (ru) 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
CA2810356C (en) 2010-09-21 2016-06-14 Purdue Pharma L.P. Buprenorphine analogs
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
MX348831B (es) 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法

Similar Documents

Publication Publication Date Title
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
EP4501322A3 (en) Lipids for use in lipid nanoparticle formulations
JP2017530984A5 (enExample)
JP2017528503A5 (enExample)
JP2016534063A5 (enExample)
HRP20151327T1 (hr) Farmaceutska kombinacija za lijeäśenje boli
JP2013534248A5 (enExample)
JP2008543854A5 (enExample)
JP2015155440A5 (enExample)
RU2008146816A (ru) Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
RU2013121788A (ru) Ингибиторы репликации вич
JP2015518004A5 (enExample)
JP2009504763A5 (enExample)
JP2010532768A5 (enExample)
JP2016531871A5 (enExample)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
JP2017523225A5 (enExample)
JP2019507781A5 (enExample)
JP2014500861A5 (enExample)
JP2011530545A5 (enExample)
JP2017531619A5 (enExample)
JP2017517565A5 (enExample)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2016510326A5 (enExample)